Search for a trial

A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy

To assess the effect of oral UT-15C with PAH-approved oral monotherapy compared to placebo with PAHapproved oral monotherapy on time to first clinical worsening event (adjudicated), as defined by at least one of the events listed below:- Death (all…

Neo* Randomized Hypertension Study

The purpose of this clinical investigation is to verify the efficacy and safety of the CVRx Neo System in subjects who qualify for the implantation for a Baroreflex Activation Therapy System compared with subjects who do not receive this device.

A SINGLE ORAL ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6836191 IN HEALTHY MALE VOLUNTEERS INCLUDING A SINGLE INTRAVENOUS DOSE OF RO6836191

The study will be performed in 2 parts, Parts 1 and Part 2. The purpose of this study is to investigate to what extent RO6836191 is tolerated. It will also be investigated how quickly and to what extent RO6836191 is absorbed and eliminated from the…

Bosentan in Exercise Induced Pulmonary Arterial Hypertension in Congenital Heart Disease

Identify congenital heart disease patients with exercise-induced pulmonary arterial hypertension. Analyze changes in pulmonary arterial pressures at peak exercise in patients with exercise induced pulmonary arterial hypertension before and after…

Denervation of the renal sympathetic nerves in heart failure with normal LV ejection fraction.

The efficacy of PRDN will be evaluated primarily using echocardiographic parameters. Also, safety of PRDN on major and minor adverse events, LV mass, LV and LA dimensions, MIBG uptake and clinical endpoints will be evaluated. The results of the…

Metabolic Syndrome Study. Renal Sympathetic Denervation for Treatment of Metabolic Syndrome Associated Hypertension

The aim of this post-CE study is to collect data on the effects of renal sympathetic denervation on the insulin resistance and muscle sympathetic nerve activity (MSNA) in patients with metabolic syndrome and associated hypertension.

A double blind, randomized, parallel, study to assess the effects of aliskiren/amlodipine and amlodipine monotherapy on ankle foot volume (AFV) in patients naïve to trial drugs with mild to moderate hypertension.

Primary objective:To assess and compare the effects of aliskiren/amlodipine and amlodipine on pedal edema after 4 weeks of treatment as measured by ankle foot volume (AFV) (water displacement method) in patients with mild to moderate hypertension.…

A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose
Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With
Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure
Following Treatment With TAK-491 40 mg Monotherapy.

The objective of this phase-3 randomized study, with a double-blind treatment period of 8 weeksduration is to evaluate the efficacy and safety of the fixed dose combinations of TAK-491 pluschlorthalidone (40/12.5 mg and 40/25 mg) in subjects with…

Effect of Olmesartan Medoxomil on arterial stiffness and thickness in subjects with metabolic syndrome.

to investigate in a descriptive way the dose-dependent effect of Olmesartan Medoxomil 20mg, 40mg en 80mg on arterial stiffness.

A RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF TRIPLE COMBINATIONS OF OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, AND HYDROCHLOROTHIAZIDE COMPARED WITH THE CORRESPONDING OLMESARTAN-AMLODIPINE COMBINATION IN SUBJECTS WITH HYPERTENSION

Primary Objective1. The main objective of this study is to demonstrate that OM/AML/HCTZ triple combinations are more efficacious in lowering SeDBP than corresponding dual combinations of OM/AML after 10 weeks of double blind treatment.Secondary…

Protocol for the clinical evaluation of wounds after topical administration of OTR4120 to ulcers.

To validate that OTR4120 will improve the healing of chronic ulcers.

A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE COMBINATION 40/10 MG ALONE

Primary: Period II (Week 8 to Week 16)1. To demonstrate the additional antihypertensive efficacy for seated diastolic blood pressure (SeDBP) gained by adding HCTZ 12.5 or 25 mg to the treatment regimen in subjects with moderate to severe HTN not…

A multicentre randomised, double blind, active controlled, parallel group comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients: The NEHIS study.

To demonstrate the superiority of the combination Nebivolol plus HCTZ versus Irbesartan plus HCTZ in terms of SBP reduction after 12 weeks of treatment in elderly patients with isolated systolic hypertension.

A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of
the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and
Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate Renal
Impairment

The primary objective of this study is to evaluate the long-term safety and tolerability of the TAK-491CLD FDC in comparison to the OLM/HCTZ FDC in hypertensive subjects with moderate renal impairment.

Catheterbased REnal SympatheCtomy for hypErteNsion after kidneyTranplantation

To test the efficacy of renal sympathetic denervation therapy with a special focus on preservation of renal allograft function.

Rheos(TM) Pivotal Trial, a Study of Baroreflex Hypertension Therapy in Refractory Hypertension.
Amendment 1: Dynamic cerebral autoregulation and lacol pulsewave velocity.
Amendment 2: Investigational Plan , revision D
Amendment 3: Investigational Plan, revision E
Amendment 4: Investigational Plan, revision F

The purpose of this clinical trial is to demonstrate the efficacy and safety of the Rheos system in subjects with JNC-7 defined stage II hypertension that is resistant to treatment with at least three anti-hypertension agents, one of which is a…

A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with essential hypertension

This study is a proof-of-efficacy, dose finding study of LCI699 in patients with mild-to-moderate uncomplicated essential hypertension in order to assess whether the BP effect, safety and tolerability of LCI699 as compared to those of placebo…

Effect of dietary proteins on blood pressure

The primary objective of the study is to demonstrate a difference in changes in fasting blood pressure and 24-hour ambulatory blood pressure after 4 weeks on a diet with a high protein content or a diet with a high carbohydrate content.Secondary…

Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.

The results of this study will give better insights in the role of ADMA in the development of systemic endothelial dysfunction.

Perindopril arginine/Amlodipine versus Valsartan/Amlodipine antihypertensive startegies: Efficacy and safety in mild to moderate hypertensive patients. A randomised, double blind 6-month study followed by 8-month open label long-term follow-up with Perindopril arginine/Amlodipine.

To assess the efficacy of blood pressure lowering and the safety of increasing doses of perindopril and amlodipine combination and to compare them to another validated antihypertensive strategy using valsartan and valsartan combined to amlodipine.